IRP-led study identifies essential genes for cancer immunotherapy
A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy.
The study, from the National Cancer Institute (NCI), was led by Nicholas Restifo, M.D., a senior investigator with NCI’s Center for Cancer Research, with coauthors from NCI; Georgetown University, Washington D.C.; the Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; New York University, New York City; and the University of Pennsylvania, Philadelphia. It was published online in Nature on August 7, 2017. NCI is part of the National Institutes of Health (NIH).
NCI researchers have identified genes that are essential for cancer cells to be killed by T cells.
This page was last updated on Friday, January 21, 2022